News and Announcements
Bioactive Laboratories Pty Ltd – CEO Interview
- Published June 25, 2014 3:34PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Bioactive Laboratories specialises in plant based solutions for human health.
They have developed the first anti-inflammatory and pain relieving agent that is gentle to the stomach. Studies show it rivals the drug efficacy and strength of NSAIDs such as Voltaren, without digestive side effects.
Global market sectors worth an estimated $560Billion annually make anti-inflammatories & pain agents the most widely used of all drugs and complementary medicines.
A faster route to market exists, than traditional biotech via the booming Complementary Medicine market to supply bulk powders & extracts.
Profitability within four years is predicted via a conservative financial model. This hybrid complementary medicine/drug development business model, suggests self funding for the development pipeline that includes drug candidates & revolutionary plant based solutions for type-2 diabetes.
Customers such as pharmaceutical & complementary medicine companies have been approached and are anxious to gain access.
To hear the latest on Bioactive Laboratories straight from the source, please listen to Rick Ferdinands, Founder & MD.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
